spacer
home > pmps > our clients
OUR CLIENTS

  PMPS 2020

          AirBridgeCargo


          Alfasigma Contract Manufacturing


          Bausch + Strobel

          Cambridge Sensotec


          Cathay Pacific


          CPhI Middle East & Africa


          CPhI Worldwide


          EMBALL’ISO


          Finnair Cargo


          FLyPharma Conference Europe


          Gerresheimer


          H&T Presspart


          Krautz-Temax


          Medical Engineering Technologies Ltd


          MedPharm


          Mikron


          Nemera


          Packline Materials


          PCI Pharma Services


          PDA


          Pharmaserve


          Phillips-Medisize


          PPMA Total Show


          Qatar Airways Cargo


           Recipharm


          Respiratory Drug Delivery


          Sensire


          SHL Group


          Turkish Cargo


          Woolcool


          Ypsomed


          Zwick-Roell


          3M


spacer


Published quarterly in
February, May,
August, and November
 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement